XFOR

0.21

7.89% -0.018

Vorhandelsmarkt: .21

X 4 Pharmaceuticals Inc (XFOR)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$0.228

Offen:

$0.23

24-Stunden-Volumen:

1.58M

Relative Volume:

0.48

Marktkapitalisierung:

$36.47M

Einnahmen:

Nettoeinkommen (Verlust:

$-16.76M

KGV:

-2.625

EPS:

-0.08

Netto-Cashflow:

$-132.97M

1W Leistung:

-22.54%

1M Leistung:

-41.70%

6M Leistung:

-66.65%

1J Leistung:

-85.71%

1-Tages-Spanne:

$0.20

$0.23

1-Wochen-Bereich:

$0.20

$0.28

52-Wochen-Spanne:

$0.20

$1.54

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

Firmenname

X 4 Pharmaceuticals Inc

Sektor

Healthcare (1163)

Branche

Biotechnology (678)

Telefon

857-529-8300

Adresse

61 NORTH BEACON STREET, BOSTON, MA

Mitarbeiter

143

Twitter

@x4pharma

Nächster Verdiensttermin

2025-03-25

Neueste SEC-Einreichungen

XFOR's Discussions on Twitter

Vergleichen Sie XFOR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
XFOR X 4 Pharmaceuticals Inc	0.21	36.47M	0	-16.76M	-132.97M	-0.08
VRTX Vertex Pharmaceuticals Inc	484.01	124.29B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.64	66.76B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	590.06	35.99B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	262.16	33.93B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	264.32	28.47B	3.81B	-644.79M	-669.77M	-6.24

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-12-12	Herabstufung	B. Riley Securities	Buy → Neutral
2023-08-30	Fortgesetzt	B. Riley Securities	Buy
2022-12-22	Eingeleitet	Cantor Fitzgerald	Overweight
2022-12-12	Eingeleitet	Piper Sandler	Overweight
2019-12-23	Eingeleitet	Oppenheimer	Outperform
2019-12-18	Eingeleitet	ROTH Capital	Buy
2019-12-09	Hochstufung	Citigroup	Neutral → Buy
2019-12-05	Eingeleitet	B. Riley FBR	Buy
2019-06-07	Eingeleitet	Stifel	Buy
2019-06-05	Eingeleitet	Cowen	Outperform

Alle ansehen

X 4 Pharmaceuticals Inc Aktie (XFOR) Neueste Nachrichten

Apr 03, 2025

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics - Quantisnow

Apr 03, 2025

Apr 01, 2025

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 01, 2025

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 01, 2025

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia - BioSpace

Apr 01, 2025

Fierce Biotech Layoff Tracker 2025: Sail cuts staff; Carisma and Inspirna shutter - Fierce Biotech

Apr 01, 2025

Mar 31, 2025

X4 Pharmaceuticals (NASDAQ:XFOR) Receives “Buy” Rating from HC Wainwright - Defense World

Mar 28, 2025

Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace

Mar 28, 2025

Mar 27, 2025

XFOR: Full Enrollment of Phase 3 4WARD Trial Expected in 2H25… - Yahoo Finance

Mar 27, 2025

Breaking Down X4 Pharmaceuticals: 4 Analysts Share Their Views - Benzinga

Mar 27, 2025

H.C. Wainwright maintains Buy on X4 Pharma, target at $1.50 - Investing.com

Mar 27, 2025

Mar 26, 2025